Table 1 Clinical characteristics of patients with advanced ESCC
Characteristics | Patients (N = 59) |
|---|---|
Age (years), median (IQR) | 67.0 (59.0–71.0) |
Age stratification, n (%) | Â |
 < 65 years | 21 (35.6) |
 ≥ 65 years | 38 (64.4) |
Sex, n (%) | Â |
 Female | 8 (13.6) |
 Male | 51 (86.4) |
BMI (kg/m2), mean ± SD | 21.1 ± 3.3 |
History of surgery related to primary lesion, n (%) | 32 (54.2) |
History of radiotherapy, n (%) | 23 (39.0) |
History of systemic chemotherapy, n (%) | 59 (100.0) |
History of targeted therapy, n (%) | 4 (6.8) |
ECOG PS, n (%) | Â |
 0 | 4 (6.8) |
 1 | 55 (93.2) |
Tumor location, n (%) | Â |
 Cervical esophagus | 8 (13.6) |
 Thoracic esophagus | 48 (81.4) |
 Abdominal esophagus | 3 (5.1) |
Tumor size (mm), median (IQR) | 30.0 (19.0–43.0) |
TNM stage, n (%) | Â |
 IV | 59 (100.0) |
Number of metastatic sites, n (%) | Â |
 1 | 39 (66.1) |
 2 | 15 (25.4) |
 3 | 3 (5.1) |
 4 | 2 (3.4) |
Location of metastases, n (%) | Â |
 Liver | 15 (25.4) |
 Lung | 8 (13.6) |
 Lymph node | 53 (89.8) |
 Other | 9 (15.3) |
Distant metastases, n (%) | 47 (79.7) |
Tumor differentiation, n (%) | Â |
 Well | 1 (1.7) |
 Moderately | 27 (45.8) |
 Moderately-to-poorly | 3 (5.1) |
 Poorly | 19 (32.2) |
 Undifferentiated | 9 (15.3) |
CEA (ng/mL), median (IQR) | 2.8 (1.8–4.7) |
TBIL (µmol/L), median (IQR) | 8.5 (6.8–12.9) |
DBIL (µmol/L), median (IQR) | 3.9 (2.9–4.9) |
IBIL (µmol/L), median (IQR) | 5.0 (3.8–8.2) |
ALT (U/L), median (IQR) | 12.5 (9.0-18.3) |
AST (U/L), median (IQR) | 17.5 (14.0–23.0) |
ALP (U/L), median (IQR) | 89.0 (68.8-110.3) |
GGT (U/L), median (IQR) | 24.0 (16.0–39.0) |
LDH (U/L), median (IQR) | 181.0 (153.3-219.3) |
ALB (g/L), mean ± SD | 39.3 ± 4.6 |
BUN (mmol/L), median (IQR) | 5.4 (4.4–6.5) |
Cr (µmol/L), mean ± SD | 73.1 ± 16.0 |
UA (µmol/L), mean ± SD | 325.7 ± 100.6 |